The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
Abstract
Type 2 diabetes is a chronic disease with disabling micro- and macrovascular complications that lead to excessive morbidity and premature mortality. It affects hundreds of millions of people and imposes an undue economic burden on populations across the world. Although insulin resistance and insulin secretory defects play a major role in the pathogenesis of hyperglycemia, several other metabolic defects contribute to the initiation/worsening of the diabetic state. Prominent among these is increased renal glucose reabsorption, which is maladaptive in patients with diabetes. Instead of an increase in renal glucose excretion, which could ameliorate hyperglycemia, there is an increase in renal glucose reabsorption, which helps sustain hyperglycemia in patients with diabetes. The sodium-glucose cotransporter (SGLT) 2 inhibitors are novel antidiabetes agents that inhibit renal glucose reabsorption and promote glucosuria, thereby leading to reductions in plasma glucose concentrations. In this article, we review the long journey from the discovery of the glucosuric agent phlorizin in the bark of the apple tree through the animal and human studies that led to the development of the current generation of SGLT2 inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Canagliflozin inhibits SGLT1 at doses > 200 mg [64].”
From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [64]
Citations
Cites
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 5×
“EGP increased after a single dose of canagliflozin in healthy subjects (14) and increased by ;17–25% after single and multiple doses of empagliflozin and dapagliflozin in patients with T2D (38,41).”
BackgroundInfluentialExpression cloning and cDNA sequencing of the Na+/glucose co-transporter
Hediger, M. A., Coady, M. J., Ikeda, T. S., & Wright, E. M. (1987) · Nature · doi:10.1038/330379a0 · Cited by 1,004
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Rossetti, L., Smith, D. J., Shulman, G. I., Papachristou, D. N., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 824
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · cited 2×
“EGP increased after a single dose of canagliflozin in healthy subjects (14) and increased by ;17–25% after single and multiple doses of empagliflozin and dapagliflozin in patients with T2D (38,41).”
BackgroundRahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G., & Brown, J. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3427 · Cited by 787
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–227 of 227
Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes
Cusi, K. J. (2017) · Contemporary diabetes · doi:10.1007/978-3-319-61013-9_4
Sodium Glucose Cotransporter-2 Inhibition and Renal Function
Rajasekeran, H. (2018) · TSpace (University of Toronto)
Sodium-Glucose Cotransporter 2 Inhibitors
DAILEY, G. E., Clarine, L., & Rodríguez-Martínez, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_34
Ertugliflozin a 2-es típusú diabetes kezelésében – a VERTIS vizsgálatsorozat első eredményei
Jermendy, G. (2018) · Diabetologia Hungarica · doi:10.24121/dh.2018.16
Baker, H. E. (2020) · IUScholarWorks (Indiana University) · doi:10.7912/c2/2031
Rohant, N., & Kennedy, J. L. W. (2021) · Heart International · doi:10.17925/hi.2021.15.1.42
A possible follow‐up method for diabetic heart failure patients
Koç, Ş. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14794
Preuss, H. G., & Bagchi, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821232-5.00017-3
刘, 昕. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.121058
Session Three: Innovating Beyond Glucose Control in Diabetes Care
Michel, L. (2017) · EMJ Diabetes · doi:10.33590/emjdiabet/10314488
Sodium-Glucose Cotransporter 2 Inhibitors
DAILEY, G. E., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_36
Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?
Cüre, M. C., & Cüre, E. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128300162240322075423
Abdullah, K., Elsharkawy, M. M., Issak, E. R., ElSerafy, A. S., Idris, S., Bendary, A., Badr, H. R., Shehata, M., & Reda, A. (2024) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2024.159026
Antidiabetic drugs and marketed formulations from natural products
Anywar, G., Adepoju, A. O., Kaggwa, B., & Mukungu, N. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30086-8.00001-2
KUMAR, V., & RAGHAVAMMA, S. (2025) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2025v18i9.55148
Arshad, M., Hoda, F., Parween, A., & Ahmad, M. K. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-02135-4
Qiu, W., Cai, A., Xiao, X., Gao, Z., Feng, Y., & Li, L. (2023) · Figshare · doi:10.6084/m9.figshare.22624847
Hwang, I.-C., Cho, G., Yoon, Y. E., Park, J. J., Park, J.-B., Lee, S.-P., Kim, H.-K., Kim, Y.-J., & Sohn, D.-W. (2020) · Figshare · doi:10.6084/m9.figshare.12386165
Qiu, W., Cai, A., Xiao, X., Gao, Z., Feng, Y., & Li, L. (2023) · Figshare · doi:10.6084/m9.figshare.22624850
Qiu, W., Cai, A., Xiao, X., Gao, Z., Feng, Y., & Li, L. (2023) · Figshare · doi:10.6084/m9.figshare.22624844
Emadi, M., Mosavizadeh-Marvest, F., Asadipour, A., Pourshojaei, Y., Hosseini, S., Mojtabavi, S., Faramarzi, M. A., Larijani, B., Mohammadi‐Khanaposhtani, M., & Mahdavi, M. (2023) · Figshare · doi:10.6084/m9.figshare.23520003
Ni, H., Geng, Y., Xu, S., Wang, Y., Sun, D., & Wang, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1776423
Abdelmobdy, A. H., Sarhan, I. I., Mansour, R. M., & Hussein, H. S. (2026) · doi:10.2196/preprints.110277
BindingDB (2021) · UC San Diego · doi:10.7270/q2dj5jxg
Metadata
- Authors
- Mudaliar, S., Polidori, D., Zambrowicz, B., & Henry, R. R.
- Affiliations
- University of California San Diego (US)
- Janssen Research & Development (United States) (US)
- Regeneron (United States) (US)
- Corresponding author
- Mudaliar, Sunder
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-11-19
- Volume
- 38
- Issue
- 12
- Pages
- 2344-2353
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2175616918
- Cited by
- 225
- References
- 60
- Citations by year
- 2026: 5 · 2025: 19 · 2024: 14 · 2023: 18 · 2022: 21 · 2021: 21 · 2020: 23 · 2019: 17 · 2018: 27 · 2017: 32 · 2016: 28
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
- Keywords
- SGLT2 inhibitors, sodium-glucose cotransporter, renal glucose reabsorption, intestinal glucose transport, type 2 diabetes, hyperglycemia, glycosuria, phloridzin, antidiabetic drug development, history of drug discovery
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Biological Transport, Diabetes Mellitus, Type 2, Glucose, Glycosuria, Humans, Hypoglycemic Agents, Insulin Resistance, Intestinal Mucosa, Kidney, Phlorhizin, Sodium-Glucose Transport Proteins, Sodium-Glucose Transporter 2, Renal Elimination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
